1701 GMT - Bayer's filing to review a lower court's decision on a case alleging the company's Roundup product caused cancer is the next step forward in the litigation, Morgan Stanley analysts say. The German pharmaceutical company argues that the "failure-to-warn" claims, on which all glyphosate cases are based, are preempted by the Federal Insecticide, Fungicide, and Rodenticide Act's labeling rules, the analyst says. The Supreme Court could potentially decide on whether or not to take the case in the second quarter, with a potential final decision by end 2025 or in the first half of 2026, they say. Shares fall 1.3% to 19.83 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 07, 2025 13:01 ET (17:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。